..
Soumettre le manuscrit arrow_forward arrow_forward ..

Volume 12, Problème 4 (2022)

Rapport de cas

Acute Erythema Multiforme Following Third Dose of an mRNA SARS-CoV-2 Vaccine

Michael Yi, Jaasrini Reddy Vellore*, Panagiotis Koutsoupias and Manish Trivedi

Erythema Multiforme (EM) is a benign hypersensitivity reaction characterized by multiple, erythematous, targetoid papules that appear most often symmetrically across the extremities. Histologically, the epidermis usually shows apoptotic keratinocytes, spongiosis, and hydropic changes. EM is associated with infections such as HSV and Mycoplasma pneumoniae and rarely with vaccinations and medications. It is an acute, self-limited disorder that resolves within 2-6 weeks. Recent studies report a variety of cutaneous findings status post mRNA COVID-19 vaccination with EM encompassing 1.1% of cutaneous findings. We report a case of a 39 y/o healthcare worker who developed acute erythema multiforme 10 days after receiving the third dose of the Moderna COVID-19 vaccine without prior adverse reactions to the first two doses. The diagnosis was made clinically, and the patient course was followed for 8 weeks without complete resolution.

Indexé dans

arrow_upward arrow_upward